Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Regulation topic
No spam. Unsubscribe anytime.
Florida committee advances bill to standardize informed consent for stem-cell therapies
Summary
The Health Professions Subcommittee favorably reported HB 1617, which would require physicians who offer stem-cell and similar biologic therapies to provide patients with defined informed-consent disclosures and clarify sourcing definitions; the measure passed the committee 16-0.
Representative Buchanan presented HB 1617 on stem-cell and related biologic therapies, saying the bill would require doctors who offer those treatments to provide informed consent and disclosure standards before administration.
The bill, Buchanan said, would give “doctors and their patients a baseline of confidence through informed consent including standards for sourcing and requiring disclosures before administration of available treatments.” He added, “Informed consent is the cornerstone of medicine ensuring ethical treatment decisions and patient centered care is more than merely signing a document. It's a communication process between the doctor and the patient.”
The committee adopted an amendment (barcode 609531) that the sponsor described as a clarification of intent and a modification to the definition of “human cells, tissues, or tissue-based products.” Representative Groh spoke in favor during debate and described personal positive experience with stem-cell therapies. Public testimony was offered but those witnesses waived speaking time; the transcript records Donald Hudspeth of CORD for Life and Aaron DiPietro of Florida Family Voice as appearing in support and waiving their testimony.
After debate the committee voted to report the bill favorably as amended by voice roll call, 16 yeas, 0 nays.
Why it matters: The measure seeks to create a uniform informed-consent process for emerging biologic treatments, which supporters said would improve patient understanding and reduce malpractice risk. The bill’s definitions and sourcing standards were the focus of the single amendment the committee adopted.
The measure now moves to the next committee stop as a reported bill.
